alexa Strategies To Overcome Intrathecal Inflammation In Progressive Multiple Sclerosis
ISSN: 2329-6895

Journal of Neurological Disorders
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Neuroimmunology & Therapeutics
December 01-02, 2016 Atlanta, USA

Bibi Bielekova
MD, Mika Komori, MD/PhD, Simone Wuest, PhD and Peter Kosa, PhD NIH/NINDS, USA
ScientificTracks Abstracts: J Neurol Disord
DOI: 10.4172/2329-6895.C1.014
Abstract
Because of inadequate efficacy of immunomodulatory treatments, primary- (PPMS) and secondary-progressive multiple sclerosis (SPMS) were thought to have significantly less intrathecal inflammation than relapsing-remitting (RRMS) MS. Using functional assays and innovative combinatorial cerebrospinal fluid (CSF) biomarkers, we demonstrated that both progressive MS subgroups have on average identical amount of intrathecal inflammation to RRMS. Instead, significantly greater level of compartmentalization of immune responses to central nervous system (CNS) tissue and greater terminal differentiation of intrathecal immune responses were characteristic of progressive MS. This makes progressive MS inflammation inaccessible to systemically-administered large molecules (e.g. monoclonal antibodies; mAb), while small molecules that may penetrate CNS are ineffective, because they predominantly target cells in proliferation cycle. Thus, in the placebo-controlled, Phase II clinical trial (RIVITALISE trial, clinicaltrials.gov identifier NCT01212094) we investigated whether intrathecal (IT) administration of mAb, such as rituximab can effectively inhibit intrathecal inflammation in SPMS. The trial was stopped for futility, after prospectively-acquired CSF biomarkers convincingly demonstrated that IT-administered rituximab decreased intrathecal inflammation only by approximately 10%. Mechanistic studies revealed following reasons for decreased efficacy of rituximab in the intrathecal, as compared to systemic compartments: 1. Due to active transport of antibodies from CSF to blood, achievable CSF concentrations of rituximab did not fully saturate CD20 on intrathecal B cells. 2. CSF lacks lytic complement, which results in decreased complement-dependent cytotoxicity (CDC). 3. The predominant cellular subtype of natural killer (NK) cells in CSF are CD56bright NK cells, which have low expression of Fc receptor and thus decreased levels of antibody-dependent cellular cytotoxicity (ADCC). In conclusion, novel immunomodulatory agents with high CNS penetrance, not dependent on CDC or ADCC and effective on proliferation-quiescent immune cells will be necessary to successfully inhibit intrathecal inflammation in progressive MS.
1. Panackal*, A., Wuest*, S.C., Lin*, Y., Wu, T., Zhang, N., Kosa, P., Komori, M., Blake, A., Browne, S.K., Rosen, L.B., Hagen, F., Levitz, S.T., Quezado, M., Hammoud, D., Bennett, J.E., Bielekova, B.# and Williamson, P.R.#: Paradoxical immune responses in non-HIV cryptococcal meningitis. Plos Pathogens 2015 May 28;11(5):e1004884.
2. Natrajan, M.S., de la Fuente, A.G., Crawford, A.H., Linehan, E., Nunez, V., Johnson, J.R., Wu, T., Fitzgerald, D.C., Ricote, M., Bielekova, B. # and Franklin, J.M.#: Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination. Brain 2015
3. Kosa, P., Komori, M., Waters, R., Wu, T., Cortese, I., Ohayon, J., Fenton, K., Cherup, J., Gedeon, T. and Bielekova, B.: Novel composite MRI scale correlates highly with disability in multiple sclerosis patients. Multiple Sclerosis and Related Disorders 2015 Nov;
4. Natrajan, M.S., Komori, M., Kosa, P., Johnson, K.R., Wu, T., Franklin, R. and Bielekova, B.: Pioglitazone enhances myelin phagocytosis & regulated multiple sclerosis monocytes. Annals of Clinical and Translational Neurology 2015 Oct 27; 2(12):1071-84; eCollection 2015
5. Lin, Y.C., Winokur, P., Blake, A., Wu, T., Manischewitz, J., King, L., Romm, E., Golding, H. and Bielekova, B.: MS patients under daclizumab therapy mount normal immune responses to influenza vaccination. Neurology, Neuroimmunology and Neuroinflammation 2016 Jan 27; 3(10):e196;
6. Komori, M., Lin, Y.C., Cortese, I., Blake, A., Ohayon, J., Cherup, J., Maric, D., Kosa, P., Wu, T. and Bielekova, B.: Insufficient disease inhibition by intrathecal rituximab in progressive MS. Annals of Translational and Clinical Neurology 2016
7. Kosa, P., Ghazali, D., Tanigawa, M., Barbour, Ch., Cortese, I., Kelley, W., Snyder, B., Ohayon, J., Fenton, K., Lehky, T., Wu, T., Greenwood, M., Nair, G. and Bielekova, B.: Development of a sensitive outcome for economical drug screening for progressive multiple sclerosis treatment. Frontiers in Neurology 2016 August 15
Biography

Bielekova received an M.D. degree in 1993 from Comenius University in Bratislava, Slovakia. After a medical internship at SUNY Downstate, Medical Center in Brooklyn and a neurology residency at Boston University, she did a 3 year postdoctoral research fellowship at the NIH/NINDS/Neuroimmunology Branch (NIB). She remained at NIB for additional 5 years as a staff physician, focusing on development of novel therapies for multiple sclerosis (MS). In 2005, she became associate professor of neurology with tenure and director of the Waddell Center for MS at University of Cincinnati. In 2008, she moved back to NINDS as an investigator. Her laboratory is studying mechanisms of immunoregulation and immune-mediated central nervous system (CNS) tissue injury in MS and other neuroimmunological diseases with a long-term goal of developing effective therapies. In addition, Dr. Bielekova is a principal investigator on several innovative protocols including adaptively-designed Phase I/II clinical trials.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords